Vaccine patch maker Vaxess raises $12M, names new CEO
Summary
Investors included RA Capital Management, Engine Ventures, GHIC and Mission Bio Capital.Cambridge, Massachusetts-based Vaxess brought in Sha as its CEO after co-founder Michael Schrader elected to step down from the corner office. Sha brings more than 20 years in life sciences, including time spent at Novartis and Genzyme. These tips release their payload of vaccines over time, mimicking how natural infections interact with the body.By allowing the immune system to mount a stronger, more durable response, they could provide more protection against disease, Vaxess says. The dissolving needles also eliminate any sharps hazard for simple patch disposal post-administration.I look forward to leading the Vaxess team as we work towards applying the MIMIX patch to many next-generation therapeutics and vaccines in partnership with life science leaders, said Sha. What started as just an idea has evolved into a company thats developed the most promising skin patch for drug delivery.